Role of preoperative neutrophil to lymphocyte ratio in prediction of recurrence, progression, and BCG failure in non-muscle invasive bladder cancer: a retrospective study

Ziani, Idriss; Ibrahimi, Ahmed; Zaoui, Youssef; Sayegh, Hachem El; Abouqal, Rédouane; Nouini, Yassine; Bouziane, Amal

doi:10.11604/pamj.2023.44.145.38621

Cited by 2 publications

(3 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cantiello et al confirmed that neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) are associated with the recurrence and progression of NMIBC, with worse oncological outcomes reported in patients with NMIBC with high NLRs and PLRs (28). Ziani et al found that preoperative NLR values could predict the recurrence, progression, and failure of NMIBC treatment (29). Serum calcium level has also been confirmed to represent a risk factor for BC metastasis and lower pretreatment serum albumin levels have been associated with poorer outcomes following RC (30).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Development and validation of a nomogram to predict lymph node metastasis in patients with progressive muscle-invasive bladder cancer

Qiao,

Jia,

Luo

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

PurposeTo develop and validate a nomogram for preoperative prediction of lymph node metastasis in patients with progressive muscle-invasive bladder cancer.Materials and methodsWe retrospectively recruited patients, divided them into training and validation cohorts, and gathered patient demographics, pathology data of transurethral bladder tumor resection specimens, imaging findings, and laboratory information. We performed logistic regression analyses, both single-variable and multi-variable, to investigate independent preoperative risk variables and develop a nomogram. Both internal and external validations were conducted to evaluate the predictive performance of this nomogram.ResultsThe training cohort consisted of 144 patients with advanced muscle-invasive bladder cancer, while the validation cohort included 62 individuals. The independent preoperative risk factors identified were tumor pathology grade, platelet count, tumor size on imaging, and lymph node size, which were utilized to develop the nomogram. The model demonstrated high predictive accuracy, as evidenced by the area under the receiver operating characteristic curve values of 0.898 and 0.843 for the primary and external validation cohorts, respectively. Calibration curves and decision curve analysis showed a good performance of the nomogram in both cohorts, indicating its high clinical applicability.ConclusionA nomogram for preoperative prediction of lymph node metastasis in patients with advanced muscle-invasive bladder cancer was successfully developed; its accuracy, reliability, and clinical value were demonstrated. This new tool would facilitate better clinical decisions regarding whether to perform complete lymph node dissection in cases of radical cystectomy.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Ziani et al. found that preoperative NLR values could predict the recurrence, progression, and failure of NMIBC treatment ( 29 ). Serum calcium level has also been confirmed to represent a risk factor for BC metastasis and lower pretreatment serum albumin levels have been associated with poorer outcomes following RC ( 30 ).…”

Section: Discussionmentioning

confidence: 99%

Development and validation of a nomogram to predict lymph node metastasis in patients with progressive muscle-invasive bladder cancer

Qiao,

Jia,

Luo

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Elevated NtL prognoses a worse recurrence-free rate and progression-free rate after 5 years of initial TURBT [16,17]. It is not entirely clear what the NtL threshold for unfavorable prognosis should be: both NtL > 2.2 and >2.5 were proved to be associated with worse BCG therapy outcomes [18,19].…”

Section: Intravesical Bcg Therapymentioning

confidence: 99%

Revolutionizing Treatment: Breakthrough Approaches for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer

Jaromin,

Konecki,

Kutwin

2024

Cancers

View full text Add to dashboard Cite

Bladder cancer is the 10th most popular cancer in the world, and non-muscle-invasive bladder cancer (NMIBC) is diagnosed in ~80% of all cases. Treatments for NMIBC include transurethral resection of the bladder tumor (TURBT) and intravesical instillations of Bacillus Calmette-Guérin (BCG). Treatment of BCG-unresponsive tumors is scarce and usually leads to Radical Cystectomy. In this paper, we review recent advancements in conservative treatment of BCG-unresponsive tumors. The main focus of the paper is FDA-approved medications: Pembrolizumab and Nadofaragene Firadenovec (Adstiladrin). Other, less researched therapeutic possibilities are also included, namely: N-803 immunotherapy, TAR-200 and TAR-210 intravesical delivery systems and combined Cabazitaxel, Gemcitabine and Cisplatin chemotherapy. Conservative treatment and delaying radical cystectomy would greatly benefit patients’ quality of life; it is undoubtedly the future of BCG-unresponsive NMIBC.

show abstract

Role of preoperative neutrophil to lymphocyte ratio in prediction of recurrence, progression, and BCG failure in non-muscle invasive bladder cancer: a retrospective study

Cited by 2 publications

References 21 publications

Development and validation of a nomogram to predict lymph node metastasis in patients with progressive muscle-invasive bladder cancer

Development and validation of a nomogram to predict lymph node metastasis in patients with progressive muscle-invasive bladder cancer

Revolutionizing Treatment: Breakthrough Approaches for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer

Contact Info

Product

Resources

About